Literature DB >> 18239285

Formulations for protecting the probiotic Saccharomyces boulardii from degradation in acidic condition.

Sandrine Graff1, Jean-Claude Chaumeil, Pierre Boy, René Lai-Kuen, Christine Charrueau.   

Abstract

Saccharomyces boulardii is a nonpathogenic yeast with proven health benefits, some of them depending on its viability. However, the living yeast is sensitive to environmental conditions and its viability is less than 1% in the faeces after oral administration. Therefore, we assessed the survival conditions of S. boulardii in aqueous suspension and in its freeze-dried form and we formulated microspheres with the former and tablets with the latter in order to preserve the viability of the probiotic. While the viability of the yeast in aqueous suspension could be maintained for one year at -20 degrees C and +5 degrees C, increasing the temperature led to almost total mortality within 14 d at +40 degrees C and 4 d at +60 degrees C. The viability of the freeze-dried yeast was preserved for one year at +25 degrees C without moisture. With 75% relative humidity, the mortality was significant at 28 d at +25 degrees C and almost total within 1 d at +60 degrees C. In vitro, whereas less than 1% of non-encapsulated or non-tabletted S. boulardii survived after 120 min at pH 1.1, both formulations in microspheres and direct compression enabled to protect the yeast from degradation in HCl and to release it viable at pH 6.8. However, despite a similar release profile from both dosage forms, the compression led to a significant decrease in the viability of the freeze-dried yeast. In conclusion, although both formulations are efficient in protecting S. boulardii in acidic condition, microspheres provide a higher entrapment efficiency and a faster release of the viable probiotic in intestinal condition than matrix tablets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18239285     DOI: 10.1248/bpb.31.266

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

3.  GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro.

Authors:  Gitte S Jensen; Kathleen F Benson; Steve G Carter; John R Endres
Journal:  BMC Immunol       Date:  2010-03-24       Impact factor: 3.615

4.  Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders.

Authors:  Theodoros Kelesidis; Charalabos Pothoulakis
Journal:  Therap Adv Gastroenterol       Date:  2012-03       Impact factor: 4.802

Review 5.  Development of microencapsulation delivery system for long-term preservation of probiotics as biotherapeutics agent.

Authors:  Himanshu K Solanki; Dipak D Pawar; Dushyant A Shah; Vipul D Prajapati; Girish K Jani; Akil M Mulla; Prachi M Thakar
Journal:  Biomed Res Int       Date:  2013-08-21       Impact factor: 3.411

6.  Evaluation of Selected Bacteria and Yeast for Probiotic Potential in Poultry Production.

Authors:  Beverly Dixon; Agnes Kilonzo-Nthenge; Maureen Nzomo; Sarayu Bhogoju; Samuel Nahashon
Journal:  Microorganisms       Date:  2022-03-22

7.  Safety assessment of a proprietary preparation of a novel Probiotic, Bacillus coagulans, as a food ingredient.

Authors:  J R Endres; A Clewell; K A Jade; T Farber; J Hauswirth; A G Schauss
Journal:  Food Chem Toxicol       Date:  2009-02-25       Impact factor: 6.023

8.  S-Adenosyl-L-methionine protects the probiotic yeast, Saccharomyces boulardii, from acid-induced cell death.

Authors:  Vincent Cascio; Daniel Gittings; Kristen Merloni; Matthew Hurton; David Laprade; Nicanor Austriaco
Journal:  BMC Microbiol       Date:  2013-02-13       Impact factor: 3.605

9.  Probiotic encapsulation technology: from microencapsulation to release into the gut.

Authors:  Gildas K Gbassi; Thierry Vandamme
Journal:  Pharmaceutics       Date:  2012-02-06       Impact factor: 6.321

10.  Dynamic In Vitro Models of the Human Gastrointestinal Tract as Relevant Tools to Assess the Survival of Probiotic Strains and Their Interactions with Gut Microbiota.

Authors:  Charlotte Cordonnier; Jonathan Thévenot; Lucie Etienne-Mesmin; Sylvain Denis; Monique Alric; Valérie Livrelli; Stéphanie Blanquet-Diot
Journal:  Microorganisms       Date:  2015-10-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.